124 related articles for article (PubMed ID: 24372055)
1. Sweet syndrome following vemurafenib therapy for recurrent cholangiocarcinoma.
Pattanaprichakul P; Tetzlaff MT; Lapolla WJ; Torres-Cabala CA; Duvic M; Prieto VG; Tsai KY; Curry JL
J Cutan Pathol; 2014 Mar; 41(3):326-8. PubMed ID: 24372055
[No Abstract] [Full Text] [Related]
2. Neutrophilic panniculitis developing after treatment of metastatic melanoma with vemurafenib.
Kim GH; Levy A; Compoginis G
J Cutan Pathol; 2013 Jul; 40(7):667-9. PubMed ID: 23581649
[TBL] [Abstract][Full Text] [Related]
3. Lesiones subcutáneas dolorosas en paciente con melanoma metastásico: un caso de paniculitis linfocítica asociado a vemurafenib.
Benavente-Villegas F; Ferrando-Roca F; Dolz-Gaitón R; Royo-Peiró M
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469793
[TBL] [Abstract][Full Text] [Related]
4. Vemurafenib-induced neutrophilic panniculitis.
Monfort JB; Pagès C; Schneider P; Neyns B; Comte C; Bagot M; Vignon-Pennamen MD; Viguier M; Lebbé C
Melanoma Res; 2012 Oct; 22(5):399-401. PubMed ID: 22828248
[TBL] [Abstract][Full Text] [Related]
5. Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.
West ES; Williams VL; Morelli JG
Pediatr Dermatol; 2015; 32(1):153-4. PubMed ID: 24602192
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib-Induced Neutrophilic Panniculitis: A New Case and Review of the Literature.
Vázquez-Osorio I; Sánchez-Aguilar MD; García-Rodiño S; Suárez-Peñaranda JM; Aliste C; Vázquez-Veiga H
Am J Dermatopathol; 2016 Jul; 38(7):e93-6. PubMed ID: 26959695
[TBL] [Abstract][Full Text] [Related]
7. Vemurafenib-induced panniculitis.
Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
[No Abstract] [Full Text] [Related]
8. BRAF inhibitor-induced neutrophilic dermatoses: a bitter-"sweet" scenario.
Heymann WR
Skinmed; 2015; 13(2):132-4. PubMed ID: 26137740
[No Abstract] [Full Text] [Related]
9. Vemurafenib-associated neutrophilic panniculitis: An emergent adverse effect of variable severity.
Maldonado-Seral C; Berros-Fombella JP; Vivanco-Allende B; Coto-Segura P; Vazquez-Lopez F; Perez-Oliva N
Dermatol Online J; 2013 Apr; 19(4):16. PubMed ID: 24021375
[TBL] [Abstract][Full Text] [Related]
10. Panniculitis in patients treated with BRAF inhibitors: a case series.
Choy B; Chou S; Anforth R; Fernández-Peñas P
Am J Dermatopathol; 2014 Jun; 36(6):493-7. PubMed ID: 24879511
[TBL] [Abstract][Full Text] [Related]
11. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature.
Ferreira J; Toda-Brito H; Moura MC; Sachse MF; Costa-Rosa J
J Cutan Pathol; 2017 Mar; 44(3):307-309. PubMed ID: 27976808
[No Abstract] [Full Text] [Related]
12. Panniculitis with arthralgia in patients with melanoma treated with selective BRAF inhibitors and its management.
Zimmer L; Livingstone E; Hillen U; Dömkes S; Becker A; Schadendorf D
Arch Dermatol; 2012 Mar; 148(3):357-61. PubMed ID: 22250191
[TBL] [Abstract][Full Text] [Related]
13. Vasculitis and panniculitis associated with vemurafenib.
Novoa RA; Honda K; Koon HB; Gerstenblith MR
J Am Acad Dermatol; 2012 Dec; 67(6):e271-2. PubMed ID: 23158633
[No Abstract] [Full Text] [Related]
14. Bumps in the Road: Panniculitis in Children and Adolescents Treated with Vemurafenib.
Finelt N; Lulla RR; Melin-Aldana H; Ruth JS; Lin FY; Su JM; Pourciau CY; Hunt RD; Kenner-Bell BM
Pediatr Dermatol; 2017 May; 34(3):337-341. PubMed ID: 28523881
[TBL] [Abstract][Full Text] [Related]
15. Case of vemurafenib-induced Sweet's syndrome.
Yorio JT; Mays SR; Ciurea AM; Cohen PR; Wang WL; Hwu WJ; Gonzalez N; Richard JL; Kim KB
J Dermatol; 2014 Sep; 41(9):817-20. PubMed ID: 24617955
[TBL] [Abstract][Full Text] [Related]
16. Neutrophilic panniculitis with vasculitis in a melanoma patient treated with vemurafenib: a case report and its management.
Ueno M; Namiki T; Inui K; Hanafusa T; Miura K; Yokozeki H
Int J Dermatol; 2017 Aug; 56(8):e163-e165. PubMed ID: 28244062
[No Abstract] [Full Text] [Related]
17. Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis.
Richarz NA; Puig L; Pérez N; Cuadra-Urteaga J; Elez E; Fernández-Figueras MT
Cancer Biol Ther; 2019; 20(3):237-239. PubMed ID: 30426827
[TBL] [Abstract][Full Text] [Related]
18. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
[No Abstract] [Full Text] [Related]
19. Severe rash associated with vemurafenib administration following nivolumab therapy.
Imafuku K; Yoshino K; Ishiwata K; Otobe S; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e84-e86. PubMed ID: 26372833
[No Abstract] [Full Text] [Related]
20. Bilateral panuveitis in a patient on vemurafenib BRAF inhibitor therapy for stage IV melanoma.
Agemy SA; Mehta AN; Pachydaki SI; Tewari A
Eur J Ophthalmol; 2014; 24(4):629-32. PubMed ID: 24474376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
